Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries

Eur J Gastroenterol Hepatol. 2014 Apr;26(4):493-4. doi: 10.1097/MEG.0000000000000054.

Authors

Bahadir Ceylan¹, Ferhat Arslan, Cem Yardimci, Muzaffer Fincanci, Nail Özgüneş

Affiliation

¹ aDepartment of Infectious Diseases and Clinical Microbiology, Medical Faculty, Bezmialem Vakif University bDepartment of Infectious Diseases and Clinical Microbiology, Medical Faculty, Medipol University cIstanbul Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology dDepartment of Infectious Diseases and Clinical Microbiology, Medical Faculty, Medeniyet University, Istanbul, Turkey.

PMID: 24598385
DOI: 10.1097/MEG.0000000000000054

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antiviral Agents / therapeutic use*
Biomarkers / blood
Drug Therapy, Combination
Female
Genotype
Hepacivirus / drug effects*
Hepacivirus / genetics
Hepatitis C, Chronic / diagnosis
Hepatitis C, Chronic / drug therapy*
Humans
Interferons / therapeutic use*
Male
Middle Aged
Poverty*
RNA, Viral / blood
Recurrence
Retreatment
Ribavirin / therapeutic use*
Time Factors
Treatment Outcome
Turkey
Viral Load

Substances

Antiviral Agents
Biomarkers
RNA, Viral
Ribavirin
Interferons